First-in-Human Study in Healthy Subjects with FR104, a Pegylated Monoclonal Antibody Fragment Antagonist of CD28

Autor: Steven Ramael, Jean-Paul Soulillou, Tim Van Assche, Weirong Wang, Ian Gourley, Maryvonne Hiance, Didier Coquoz, Caroline Mary, Cécile Braudeau, Régis Josien, Nicolas Poirier, Gilles Blancho, Virginie Thepenier, Jos Lempoels, Bernard Vanhove, Nina Salabert, Ian Anderson

Publikováno v: Journal of Immunology
Journal of Immunology, Publisher : Baltimore : Williams & Wilkins, c1950-. Latest Publisher : Bethesda, MD : American Association of Immunologists, 2016, 197 (12), pp.4593-4602. ⟨10.4049/jimmunol.1601538⟩
Journal of Immunology, 2016, 197 (12), pp.4593-4602. ⟨10.4049/jimmunol.1601538⟩

FR104 is a monovalent pegylated Fab′ Ab, antagonist of CD28, under development for treatment of transplant rejection and autoimmune diseases. In contrast to CD80/86 antagonists (CTLA4-Ig), FR104 selectively blunts CD28 costimulation while sparing C

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::322ff4e24a61b4626e20c89805e07a2e
https://doi.org/10.4049/jimmunol.1601538